These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17666913)

  • 21. Prolongation of ventricular refractoriness by class Ia antiarrhythmic drugs in the prevention of ventricular tachycardia induction.
    Kus T; Costi P; Dubuc M; Shenasa M
    Am Heart J; 1990 Oct; 120(4):855-63. PubMed ID: 2220538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Electrophysiologic effects of bepridil in the anesthetized dog studied by endocardiac electrodes.
    Sassine A; Masse C; Fajuri A; Hirsch JL; Labrid C; Puech P
    Am J Cardiol; 1984 Jun; 53(11):1707-11. PubMed ID: 6610347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
    Mao ZL; Wheeler JJ; Clohs L; Beatch GN; Keirns J
    J Clin Pharmacol; 2009 Jan; 49(1):17-29. PubMed ID: 18927241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influences of rapid pacing-induced electrical remodeling on pharmacological manipulation of the atrial refractoriness in rabbits.
    Chiba T; Kondo N; Takahara A
    J Pharmacol Sci; 2016 Mar; 130(3):170-6. PubMed ID: 27032905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Electrophysiologic effects of intravenous carocainide].
    Zannad F; Aliot E; Baille N; Gilgenkrantz JM
    Arch Mal Coeur Vaiss; 1986 Feb; 79(2):236-41. PubMed ID: 3085623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vernakalant: A novel agent for the termination of atrial fibrillation.
    Finnin M
    Am J Health Syst Pharm; 2010 Jul; 67(14):1157-64. PubMed ID: 20592320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
    Torp-Pedersen C; Raev DH; Dickinson G; Butterfield NN; Mangal B; Beatch GN
    Circ Arrhythm Electrophysiol; 2011 Oct; 4(5):637-43. PubMed ID: 21841207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical electrophysiological effects of intravenous recainam: an antiarrhythmic drug under investigation for the treatment of ventricular and supraventricular arrhythmias.
    Feld GK; Luceri RM; Greenspon AJ; Singh BN; Horowitz LN; Capuzzi DM; Frame VB; Myerburg RJ
    Pacing Clin Electrophysiol; 1991 Jul; 14(7):1129-37. PubMed ID: 1715550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation.
    Naccarelli GV; Wolbrette DL; Samii S; Banchs JE; Penny-Peterson E; Stevenson R; Gonzalez MD
    Expert Opin Investig Drugs; 2008 May; 17(5):805-10. PubMed ID: 18447605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans.
    Sager PT; Nademanee K; Antimisiaris M; Pacifico A; Pruitt C; Godfrey R; Singh BN
    Circulation; 1993 Sep; 88(3):1072-82. PubMed ID: 8353869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential effects of autonomic blockade on sinus and atrioventricular nodal function in normals and in intrinsic sinus node dysfunction.
    Sethi KK; Balachandar J; Jaishankar S; Gupta MP
    Int J Cardiol; 1986 Aug; 12(2):233-42. PubMed ID: 3744602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent.
    Fedida D
    Expert Opin Investig Drugs; 2007 Apr; 16(4):519-32. PubMed ID: 17371199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vernakalant in the management of atrial fibrillation.
    Cheng JW
    Ann Pharmacother; 2008 Apr; 42(4):533-42. PubMed ID: 18334607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerance and effects of almokalant, a new selective Ik blocking agent, on ventricular repolarization and on sino-atrial and atrioventricular nodal function in the heart: a study in healthy, male volunteers utilizing transesophageal atrial stimulation.
    Darpö B; Almgren O; Bergstrand R; Bäärnhielm C; Gottfridsson C; Sandstedt B; Edvardsson N
    J Cardiovasc Pharmacol; 1995 May; 25(5):681-90. PubMed ID: 7630145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic Review and Meta-analysis Appraising Efficacy and Safety of Vernakalant for Cardioversion of Recent-Onset Atrial Fibrillation.
    Ma W; Guo X; Wang Q; Sun G; Wang J
    J Cardiovasc Pharmacol; 2020 Jul; 76(1):32-41. PubMed ID: 32251022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical electrophysiology of intravenous indecainide.
    Horowitz LN; Spielman SR; Webb CR; Morganroth J; Greenspan AM
    Am Heart J; 1985 Oct; 110(4):784-8. PubMed ID: 4050649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vernakalant hydrochloride: A novel atrial-selective agent for the cardioversion of recent-onset atrial fibrillation in the emergency department.
    Stiell IG; Dickinson G; Butterfield NN; Clement CM; Perry JJ; Vaillancourt C; Calder LA
    Acad Emerg Med; 2010 Nov; 17(11):1175-82. PubMed ID: 21175515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Electrophysiological effects of MS-551 in humans: a class III antiarrhythmic agent.
    Isomoto S; Konoe A; Centurion OA; Hayano M; Kaibara M; Hirata T; Yano K
    Pacing Clin Electrophysiol; 1995 Nov; 18(11):2022-7. PubMed ID: 8552516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the in vivo hemodynamic effects of the antiarrhythmic agents vernakalant and flecainide in a rat hindlimb perfusion model.
    Allison B; Yang Y; Pourrier M; Gibson JK
    J Cardiovasc Pharmacol; 2011 Apr; 57(4):463-8. PubMed ID: 21283020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of intravenous anesthetics on atrial wavelength and atrioventricular nodal conduction in guinea pig heart. Potential antidysrhythmic properties and clinical implications.
    Napolitano CA; Raatikainen MJ; Martens JR; Dennis DM
    Anesthesiology; 1996 Aug; 85(2):393-402. PubMed ID: 8712456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.